Article
Effective July 1, the Pharmaceutical Research and Manufacturers of America (PhRMA) adopts its new voluntary PhRMA Code on Interactions with Healthcare Professionals.
Over 300 patients randomized in Ocular Therapeutix's SOL-1 phase 3 trial for OTX-TKI
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Foundation Fighting Blindness joins University of Colorado Anschutz Medical Campus and leading institutions receive funding to fast track whole eye transplantation program
Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD
PolyActiva’s PA5108 glaucoma implant shows promising results in clinical trial, paving the way for long-term drug delivery
Prevent Blindness providing free educational resources on geographic atrophy